Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Schizophrenia presents a substantial clinical and economic burden to the health-care system. In QUAlity of LIfe with AbiliFY Maintena (QUALIFY), a randomized head-to-head study of aripiprazole once-monthly 400 mg (AOM 400) compared with paliperidone palmitate (PP; 78–234 mg/mo), AOM 400 demonstrated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker, Anna Eramo
Formato: Artigo
Idioma:Inglês
Publicado em: BioExcel Publishing Ltd 2016-09-01
Colecção:Drugs in Context
Assuntos:
aripiprazole once-monthly
paliperidone palmitate
schizophrenia
cost-effectiveness
long-acting injectable agents
second-generation antipsychotic
health economics
patient functioning
Acesso em linha:http://www.drugsincontext.com/pharmacoeconomic-comparison-of-aripiprazole-once-monthly-and-paliperidone-palmitate-from-a-head-to-head-clinical-trial-in-schizophrenia-a-us-analysis/
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados